Gallium compounds as antineoplastic agents

Current Opinion in Oncology

Volumn 16, Issue 6, 2004, Pages 547-552

  Chitambar, Christopher R ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Bladder cancer; Gallium; Iron; Lymphoma; Ribonucleotide reductase; Transferrin receptors

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GALLIUM NITRATE; HYDROXYUREA; IFOSFAMIDE; METHOTREXATE; MITOGUAZONE; RIBONUCLEOTIDE REDUCTASE; TRANSFERRIN; TRANSFERRIN RECEPTOR; VINBLASTINE;

ANEMIA; APOPTOSIS; BLADDER CANCER; BONE MARROW SUPPRESSION; BONE METABOLISM; CANCER SURGERY; CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DNA MICROARRAY; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG RESPONSE; EYE TOXICITY; HEARING LOSS; HODGKIN DISEASE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; LEUKOPENIA; LYMPHOCYTOMA; LYMPHOMA; LYMPHOMA CELL; LYMPHOPROLIFERATIVE DISEASE; METASTASIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; THROMBOCYTOPENIA; TREATMENT FAILURE; UROGENITAL TRACT TUMOR;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; GALLIUM; HUMANS; LYMPHOMA; URINARY BLADDER NEOPLASMS;

EID: 8344260657     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000142071.22226.d2     Document Type: Review

References (61)

1. Hart MM, Adamson RH: Antitumor activity and toxicity of salts of inorganic group IIIa metals: aluminum, gallium, indium and thallium. Proc Natl Acad Sci USA 1971, 68:1623-1626.
2. Adamson RH, Canellos GP, Sieber SM: Studies on the antitumor activity of gallium nitrate (NSC-I5200) and other group IIIa metal salts. Cancer Chemother Rep 1975, 59:599-610.
3. Weick JK, Stephens RL, Baker LH, et al.: Gallium nitrate in malignant lymphoma: a Southwest Oncology Group study. Cancer Treat Rep 1983, 67:823-825.
4. Warrell RP Jr, Coonley CJ, Straus DJ, et al.: Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer 1983, 51:1982-1987.
5. Keller J, Bartolucci A, Carpenter JT Jr, et al.: Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1986, 70:1221-1223.
6. Warrell RP Jr, Danieu L, Coonley CJ, et al.: Salvage chemotherapy of advanced lymphoma with investigational drugs: mitoguazone, gallium nitrate and etoposide. Cancer Treat Rep 1987, 71:47-51.
7. Chitambar CR, Zahir SA, Ritch PS, et al.: Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma. Am J Clin Oncol 1997, 20:173-178.
8. Einhorn L: Gallium nitrate in the treatment of bladder cancer. Semin Oncol 2003, 30:34-41. This is a review of studies of gallium nitrate for the treatment of urothelial malignancies.
9. Todd PA, Fitton A: Gallium nitrate: a review of its pharmacological properties and therapeutic potential in cancer-related hypercalcemia. Drugs 1991, 42:261-273.
10. Harris WR, Pecoraro VL: Thermodynamic binding constants for gallium transferrin. Biochemistry 1983, 22:292-299.
11. Baker E, Morgan EH: Iron transport. In Iron Metabolism in Health and Disease. Edited by Brock JH, Halliday JW, Pippard MJ, et al. Philadelphia: WB Saunders; 1994:63-95.
12. Vallabhajosula SR, Harwig JF, Siemsen JK, et al.: Radiogallium localization in tumors: blood binding and transport and the role of transferrin. J Nucl Med 1980, 21:650-656.
13. Allamneni KP, Burns RB, Gray DJ, et al.: Gallium maltolate treatment results in transferrin-bound gallium in patient serum [abstract 1013]. Proc Am Assoc Cancer Res 2004, 45:230. This paper studies a novel oral gallium formulation.
14. Larson SM, Rasey JS, Allen DR, et al.: Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Natl Cancer Inst 1980, 64:41-53.
15. Chitambar CR, Zivkovic Z: Uptake of gallium-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin-independent mechanisms. Cancer Res 1987, 47:3929-3934.
16. Horton MA: Expression of transferrin receptors during erythroid maturation. Exp Cell Res 1983, 144:361-366.
17. Sieff C, Bicknell D, Gaine G, et al.: Changes in cell surface antigen expression during hemopoietic differentiation. Blood 1982, 60:703-713.
18. Larrick JW, Cresswell P: Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J Supramol Struct 1979, 11:579-586.
19. Chitambar CR, Massey EJ, Seligman PA: Regulation of transferrin receptor expression on human leukemic cells during proliferation and induction of differentiation. Effects of gallium and dimethylsulfoxide. J Clin Invest 1983, 72:1314-1325.
20. Forsbeck K, Nilsson K: The dynamic morphology of the transferrin - transferrin receptor system in human leukaemia/lymphoma cell lines and its relation to iron metabolism and cell proliferation. Scand J Haematol 1985, 35:145-154.
21. Thelander L, Reichard P: Reduction of ribonucleotides. Annu Rev Biochem 1979, 48:133-158.
22. Petersson L, Gräslund A, Ehrenberg A, et al.: The iron center in ribonucleotide reductase from Escherichia coli. J Biol Chem 1980, 255:6706-6712.
23. Nutter LM, Cheng Y-C: Nature and properties of mammalian ribonucleoside diphosphate reductase. In Inhibitors of Ribonucleoside Diphosphate Reductase Activity. Edited by Cory JG, Cory AH. New York: Pergamon Press; 1989:37-54.
24. Habeshaw JA, Lister TA, Stansfeld AG: Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet 1983, i:498-501.
25. Kvaloy S, Langholm R, Kaalhus O, et al.: Transferrin receptor and B-lymphoblast antigen - their relationship to DNA synthesis, histology and survival in B-cell lymphomas. Int J Cancer 1984, 33:173-177.
26. Smith NW, Strutton GM, Walsh MD, et al.: Transferrin receptor expression in primary superficial human bladder tumours identifies patients who develop recurrences. Br J Urol 1990, 65:339-344.
27. Basar I, Ayhan A, Bircan K, et al.: Transferrin receptor activity as a marker in transitional cell carcinoma of the bladder. Br J Urol 1991, 67:165-168.
28. Chitambar CR, Seligman PA: Effects of different transferrin forms on transferrin receptor expression, iron uptake and cellular proliferation of human leukemic HL60 cells: mechanisms responsible for the specific cytotoxicity of transferrin-gallium. J Clin Invest 1986, 78:1538-1546.
29. Chitambar CR, Matthaeus WG, Antholine WE, et al.: Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood 1988, 72:1930-1936.
30. Chitambar CR, Narasimhan J, Guy J, et al.: Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells. Cancer Res 1991, 51:6199-6201.
31. Narasimhan J, Antholine WE, Chitambar CR: Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase. Biochem Pharmacol 1992, 44:2403-2408.
32. Medley DW, Tripp ED, Slowiaczek P, et al.: Effect of gallium on DNA synthesis by human T-cell lymphoblasts. Cancer Res 1988, 48:3014-3018.
33. Haq RU, Wereley JP, Chitambar CR: Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp Hematol 1995, 23:428-432.
34. Chitambar CR, Wereley JP, Matsuyama S: Mechanisms of antineoplastic activity of gallium nitrate in lymphoma: protein ubiquitination and the induction of apoptosis through a Bax and mitochondrial pathway [abstract 5317]. Proc Am Assoc Cancer Res 2004, 45:1226. This recent basic investigation shows that gallium activates caspases and induces apoptosis in lymphoma cell lines. Exposure of cells to gallium nitrate results in protein ubiquitination. The cytotoxic effects of gallium nitrate are enhanced by the proteosome inhibitor bortezomib.
35. Chitambar CR, Wereley JP, Heiman T, et al.: Cellular adaptation to down-regulated iron transport into lymphoid leukaemic cells: effects on the expression of the gene for ribonucleotide reductase. Biochem J 2000, 345:681-685.
36. Chitambar CR, Wereley JP: Resistance to the antitumor agent gallium nitrate in human leukemic cells is associated with decreased gallium/iron uptake, increased activity of iron regulatory protein-1, and decreased ferritin production. J Biol Chem 1997, 272:12151-12157.
37. Schlicht M, Wereley JP, Datta MW, et al.: Identification of biomarkers for tumor sensitivity and resistance to the antineoplastic drug gallium nitrate in non-Hodgkin's lymphoma [abstract 5766]. Proc Am Assoc Cancer Res 2003, 44:1322. In this study, complementary DNA microarray analysis of gallium-resistant and gallium-sensitive CCRF-CEM lymphoma/leukemic cells was conducted to search for differences in gene expression that might be responsible for the development of drug resistance to gallium nitrate. The analysis suggested that genes involved in the trafficking of proteins to lysosomes were downregulated in gallium-resistant cells. Further studies are needed to confirm these findings.
38. Chitambar CR, Seigneuret MC, Matthaeus WG, et al.: Modulation of lymphocyte proliferation and immunoglobulin production by transferrin-gallium. Cancer Res 1989, 49:1125-1129.
39. Drobyski WR, Haq RU, Majewski D, et al.: Modulation of in vitro and in vivo T-cell responses by transferrin-gallium and gallium nitrate. Blood 1996, 88:3056-3064.
40. Matkovic V, Balboa A, Clinchot D, et al.: Gallium prevents adjuvant arthritis in rats and interferes with macrophage/T-cell function in the immune response. Curr Ther Res 1991, 50:255-267.
41. Orosz CG, Wakely E, Bergese SD, et al.: Prevention of murine cardiac allograft rejection with gallium nitrate. Comparison with anti-CD4 monoclonal antibody. Transplantation 1996, 61:783-791.
42. Whitacre C, Apseloff G, Cox K, et al.: Suppression of experimental autoimmune encephalomyelitis by gallium nitrate. J Neuroimmunol 1992, 39:175-181.
43. Waalkes TP, Sanders K, Smith RG, et al.: DNA polymerases of Walker 256 carcinosarcoma. Cancer Res 1974, 34:385-391.
44. Berggren MM, Burns LA, Abraham RT, et al.: Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate. Cancer Res 1993, 53:1862-1866.
45. Anghileri LJ, Thuvenot P, Brunotte F, et al.: Ionic competition and 67Ga in vivo accumulation. Nuklearmedizin 1982, 21:114-116.
46. Perchellet EM, Ladesich JB, Collery P, et al.: Microtubule-disrupting effects of gallium chloride in vitro. Anticancer Drugs 1999, 10:477-488.
47. Makkonen N, Hirvonen M-R, Savolainen K, et al.: The effect of free gallium and gallium in liposomes on cytokine and nitric oxide secretion from macrophage-like cells in vitro. Inflamm Res 1995, 44:523-528.
48. Bernstein LR: Mechanisms of therapeutic activity for gallium. Pharmacol Rev 1998, 50:665-682.
49. Collery P, Keppler B, Madoulet C, et al.: Gallium in cancer treatment. Crit Rev Oncol Hematol 2002, 42:283-296.
50. Bockman R: The effects of gallium nitrate on bone resorption. Semin Oncol 2003, 30:5-12. This is a review of the action of gallium on bone metabolism.
51. Crawford ED, Saiers JH, Baker LH, et al.: Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group study. Urology 1991, 38:355-357.
52. Seidman AD, Scher HI, Heinemann MH, et al.: Continuous infusion gallium nitrate for patients with advanced refractory urothelial tumors. Cancer 1991, 68:2561-2565.
53. Seligman PA, Crawford ED: Treatment of advanced transitional cell carcinoma of the bladder with continuous infusion gallium nitrate. J Natl Cancer Inst 1991, 83:1582-1584.
54. Einhorn LH, Roth BJ, Ansari R, et al.: Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 1994, 12:2271-2276.
55. Dreicer R, Propert KJ, Roth BJ, et al.: Vinblastine, ifosfamide, and gallium nitrate - an active new regimen in patients with advanced carcinoma of the urothelium. Cancer 1997, 79:110-114.
56. McCaffrey JA, Hilton S, Mazumdar M, et al.: Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin and cisplatin in patients with advanced transitional-cell carcinoma. J Clin Oncol 1997, 15:2449-2455.
57. Kelsen DP, Alcock N, Yeh S, et al.: Pharmacokinetics of gallium nitrate in man. Cancer 1980, 46:2009-2013.
58. Lundberg JL, Chitambar CR: Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells. Cancer Res 1990, 50:6466-6470.
59. Myette MS, Elford HL, Chitambar CR: Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase. Cancer Lett 1998, 129:199-204.
60. Chitambar CR, Wereley JP, Haq RU: Synergistic inhibition of T-lymphoblastic leukemic CCRF-CEM cell growth by gallium and recombinant human α-interferon through action on cellular iron uptake. Cancer Res 1994, 54:3224-3228.
61. Hata Y, Sandler A, Loehrer PJ, et al.: Synergism of Taxol and gallium nitrate in human breast carcinoma cells: schedule dependency. Oncol Res 1994, 6:19-24.